How does national legislation in different EU member states compare and how effective is the adding of new psychoactive substances (NPS) to the existing schedules of drug laws versus legislative experimentation designing new schedules or applying controls under medicines or consumer protection regulations?
While in the Americas cannabis policy reform is taking off, Europe seems to be lagging behind. At the level of national governments denial of the changing policy landscape and inertia to act upon calls for change reigns. At the local level, however, disenchantment with the current cannabis regime gives rise to new idea.
Cannabis was condemned by the 1961 Single Convention on Narcotic Drugs as a psychoactive drug with “particularly dangerous properties” and hardly any therapeutic value. Ever since, an increasing number of countries have shown discomfort with the treaty regime’s strictures through soft defections, stretching its legal flexibility to sometimes questionable limits.
The upsurge in violence in Central America’s Northern Triangle is often named in one breath with the drugs market. While violence clearly thrives from an illegal trade met with exclusively repressive state responses, assumptions on cause and effect are frequently flawed or blurred.